BARDA Procures NexoBrid for Emergency Response

MediWound Ltd. and its U.S. commercial partner Vericel Corporation have announced that BARDA has begun procuring NexoBrid for emergency stockpile as part of the HHS mission to build national preparedness for public health medical emergencies.

BARDA purchased inventory will be managed by MediWound under vendor managed inventory. The initial BARDA procurement is valued at $16.5 million, with the first delivery of NexoBrid expected by the end of the first quarter of 2020 and additional deliveries occurring over the subsequent five quarters. In addition, BARDA holds an option to procure additional quantities of NexoBrid through funding of up to $50 million. The submission of the Biologics License Application (BLA) for NexoBrid to the U.S. Food & Drug Administration (FDA) is planned for the second quarter of 2020.

NexoBrid is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns within four hours of application without harming viable tissue. NexoBrid is approved in the European Union and other international markets and has been designated as an orphan biologic drug in the United States, European Union and other international markets.

 

Tags: CBRNe, Medical Countermeasure

Our Current Sponsors